iifl-logo

Venus Remedies Ltd Nine Monthly Results

452.6
(-0.09%)
Sep 12, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Dec-2024Dec-2023Dec-2022Dec-2021Dec-2020

Gross Sales

452.92

406.29

399.87

456.72

436.75

Excise Duty

0

0

0

0

0

Net Sales

452.92

406.29

399.87

456.72

436.75

Other Operating Income

0

0

0

0

0

Other Income

24.1

7.66

7.04

6.06

19.03

Total Income

477.02

413.95

406.91

462.78

455.78

Total Expenditure

418.39

366.06

364.29

400.15

387.47

PBIDT

58.63

47.89

42.62

62.63

68.31

Interest

0.05

0.19

0.41

0.48

12.06

PBDT

58.58

47.7

42.21

62.15

56.25

Depreciation

17.78

20.53

24.01

25.97

25.9

Minority Interest Before NP

0

0

0

0

0

Tax

13.65

6.84

0

-4.31

3.7

Deferred Tax

2.81

2.36

2.69

0

0

Reported Profit After Tax

24.34

17.97

15.51

40.49

26.66

Minority Interest After NP

0

0

0

0

0

Net Profit after Minority Interest

24.34

17.97

15.51

40.49

26.66

Extra-ordinary Items

5.91

0

0

0

2.54

Adjusted Profit After Extra-ordinary item

18.43

17.97

15.51

40.49

24.12

EPS (Unit Curr.)

18.2

13.44

11.6

30.68

21.6

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

0

0

0

0

Equity

13.37

13.37

13.37

13.37

12.34

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

12.94

11.78

10.65

13.71

15.64

PBDTM(%)

12.93

11.74

10.55

13.6

12.87

PATM(%)

5.37

4.42

3.87

8.86

6.1

Venus Remedies: Related NEWS

Venus Remedies Secures Ukrainian GMP Certification for Baddi Facility

The Unit-II Baddi plant, which got the renewed certification, has state-of-art infrastructure and state-of-the-art manufacturing technology to cater to complex therapeutic segments in an efficient manner. 

22 May 2025|12:41 PM
Read More
Venus Remedies Secures Key Approvals, Strengthens Global Market Reach

The company is now set to further expand into Eastern Europe as this recognition ensures patients and healthcare providers have access to reliable and effective antibiotics.

31 Dec 2024|09:16 PM
Read More
Venus Remedies gets approval for pre-filled syringe facility

Furthermore, the NPRA's recognition will enable Venus Remedies to capitalise on the expanding global demand for enoxaparin.

6 Nov 2024|10:36 AM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.